| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(4 years from now) | |
Kerendia is owned by Bayer Hlthcare.
Kerendia contains Finerenone.
Kerendia has a total of 1 drug patent out of which 0 drug patents have expired.
Kerendia was authorised for market use on 09 July, 2021.
Kerendia is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Kerendia from 09 July, 2025.
The generics of Kerendia are possible to be released after 12 April, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 09, 2026 |
| M(M-279) | Sep 01, 2025 |
Drugs and Companies using FINERENONE ingredient
NCE-1 date: 09 July, 2025
Market Authorisation Date: 09 July, 2021
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
KERENDIA family patents
